DARTMOUTH, Nova Scotia, Oct. 23, 2018 (GLOBE NEWSWIRE) -- IMV Inc. (“IMV” or the “Corporation”) (Nasdaq: IMV; TSX: IMV), a
clinical stage immunotherapy company, announced today that it will hold a conference call and webcast on Friday, November 2, 2018
at 8:00 a.m. ET to discuss the company’s third quarter financial and operational results.
The dial-in number for the conference call is (844) 461-9932 (U.S. and Canada) or (636) 812-6632 (international) with the
conference ID: 5779058. Those interested can access the live audio webcast at this link: https://edge.media-server.com/m6/p/rrkkk65v. The
webcast will be recorded and available on the IMV website for 30 days following the call.
About IMV
IMV Inc., formerly Immunovaccine, is a clinical stage biopharmaceutical company dedicated to making
immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and other serious
diseases. IMV is pioneering a new class of immunotherapies based on the Company’s proprietary drug delivery platform. This patented
technology leverages a novel mechanism of action that enables the reprogramming of immune cells in vivo, which are aimed
at generating powerful new synthetic therapeutic capabilities. IMV’s lead candidate, DPX-Survivac, is a T cell activating
immunotherapy that combines the utility of the platform with a target: survivin. IMV is currently conducting eight Phase 2 studies
with Incyte and Merck assessing DPX-Survivac as a combination therapy in six different indications. Connect at www.imv-inc.com.
IMV Forward-Looking Statements
This press release contains forward-looking information under applicable Canadian and U.S. securities law.
All information that addresses activities or developments that we expect to occur in the future is forward-looking
information. Although the Corporation believes the forward-looking statements in this press release are reasonable, it can
give no assurance that the expectations and assumptions in such statements will prove to be correct. The Corporation cautions
investors that any forward-looking statements by the Corporation are not guarantees of future results or performance, and that
actual results may differ materially from those in forward-looking statements as a result of various factors, including, but not
limited to, the matters discussed under “Risk Factors and Uncertainties” in IMV’s Annual Information Form filed in Canada on
March 20, 2018 on www.sedar.com and included in
the company’s Form 40-F filing in the United States with the United States Securities and Exchange Commission filed on May 1, 2018
on www.sec.gov. IMV Inc. assumes no responsibility to
update forward-looking statements in this press release except as required by law.
Contacts for IMV:
MEDIA
Mike Beyer, Sam Brown Inc.
T: (312) 961-2502 E: mikebeyer@sambrown.com
INVESTOR RELATIONS
Pierre Labbé, Chief Financial Officer
T: (902) 492-1819 E: info@imv-inc.com
Patti Bank, Managing Director, Westwicke Partners
O: (415) 513-1284
T: (415) 515-4572 E: patti.bank@westwicke.com
